[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Ghent\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":665},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,122,0,25,[9,45,75,101,119,145,173,206,240,265,290,315,339,365,390,413,437,462,489,508,537,562,585,610,639],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100622723","validation-of-new-semg-electrode-placement-guidelines-for-the-triceps-surae-in-post-stroke-individuals-100622723",false,"NCT07387328","Validation of New sEMG Electrode Placement Guidelines for the Triceps Surae in Post-stroke Individuals","Vest-P","Inclusion Criteria:\n\n* Adult individuals who have experienced a stroke (CVA or cerebrovascular accident).\n* Have no other neurological disorder.\n* Are able to lie in the prone position for approximately one and a half hours.\n* Are able to walk without shoes for the walking component (only applicable to participants who will perform walking). The use of an assistive device such as a walking stick (or similar) is permitted.\n\nExclusion Criteria:\n\n* Presence of other neurological or orthopedic conditions that may influence the measurements and results (e.g., Parkinson's disease, peripheral neuropathy of the lower limbs, severe ankle osteoarthritis limiting range of motion, etc.).\n* Having undergone a surgical intervention on the hemiparetic lower leg (e.g., ankle joint arthrodesis, etc.).\n* Severe cognitive impairments that prevent understanding participation in the study (assessed using the AbilityQ).","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","1 Day","OBSERVATIONAL","Background and rationale:\n\nSurface electromyography (EMG) is a non-invasive method to measure muscle activity, among others in people after a stroke during gait analysis. Measurement quality is strongly influenced by electrode placement. However, the commonly used SENIAM guidelines do not take individual variations in muscle morphology into account, which can lead to inaccurate measurements. In previous research demonstrated that the standard placement on the triceps surae (medial and lateral gastrocnemius and soleus) was suboptimal at the group level and sometimes even problematic at the individual level. Therefore, new placement guidelines (EPICA guidelines, Electrode Placement for Individual Calf Anatomy) were developed, which are currently being tested in healthy individuals.\n\nMethod:\n\nIn this project aims to validate these newly developed guidelines in people after a stroke who exhibit atrophy of their calf muscles. For each participant, electrode positions on the hemiplegic side will be determined according to our guidelines while the participant is lying prone. Circular stickers will be used instead of actual EMG electrodes and will be placed according to the EPICA guidelines as well as according to the SENIAM guidelines. Subsequently, the muscle borders of the triceps surae will be identified on the participant's leg using 2D ultrasound. Afterwards, the distance between the electrodes and the surrounding muscle borders will be measured to map electrode placement on the muscle in order to validate the guidelines.\n\nIn the second part of this study, 3D ultrasound recordings will be made of the soleus, medial gastrocnemius, and lateral gastrocnemius with the electrodes (stickers) on these muscles, so that during image processing, electrode positions can be visualized relative to the entire muscle, including along the depth axis. In addition, participants who can safely walk without an ankle-foot orthosis will be asked to walk a maximum of five times ten meters. Additionally, an ultrasound probe will be attached to the leg to investigate how the electrode position relates to the muscle-tendon junction during movement. Subsequently, actual electrodes will also be placed to record muscle activity during walking and heel raises.\n\nFurthermore, all participants will be asked to do a heel raise to activate the calf muscles. As such, the quality of the EMG signals will be evaluated. Other measurements will included: Fugl-Meyer Assessment of the lower limb, measure passive ankle range of motion with a goniometer, and measure lower leg length with a tape measure. These will be used as descriptive parameters of our study population.\n\nPatients will be asked on a voluntary basis to participate in a second, short measurement approximately two weeks after the first session. During this measurement, electrode placement will again be performed according to the EPICA guidelines. 3D ultrasound will again be used to calculate the distances between the electrodes and the muscle borders. This second measurement is necessary to investigate the test-retest reliability of the EPICA guidelines in people after a stroke.",[26],"Stroke",[28,29,30,31],"Surface electromyography","guidelines","SENIAM","3D freehand ultrasound","RECRUITING","2026-06-01",{"date":35,"type":36},"2026-06-03","ACTUAL",{"date":38,"type":36},"2026-04-17",{"date":40,"type":21},"2027-10-31",{"name":42,"class":43},"University Hospital, Ghent","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100637688","assessment-of-endoscopic-tip-control-using-a-novel-score-based-on-snare-tip-soft-coagulation-of-ex-vivo-model-ham-study-100637688","NCT07609017","Assessment of Endoscopic Tip Control Using a Novel Score Based on Snare Tip Soft Coagulation of ex Vivo Model (HAM STUDY)","Inclusion Criteria:\n\n* Digestive endoscopists at any level of training (trainee, consultant endoscopist, or advanced\u002Finterventional endoscopist)\n* Signed informed consent for study participation\n\nExclusion Criteria:\n\n* No signed informed consent for study participation",true,"65 Years",{"count":54,"type":21},71,"INTERVENTIONAL",[57],"NA","Introduction: Colorectal cancer (CRC) is a significant global health concern, with colonoscopy being the primary screening tool for its detection and treatment. Endoscopic techniques such as snare tip soft coagulation (STSC) play a crucial role in reducing adenoma recurrence post-resection. However, assessing endoscopists' proficiency in tip control during these procedures remains challenging. This study aims to develop and validate a web-based scoring system to objectively evaluate endoscopist tip control during STSC application.\n\nResearch Questions:\n\n* Can STSC application on an ex vivo model effectively measure endoscopic tip control across different levels of endoscopists' experience?\n* Is there a correlation between tip control and endoscopists' polypectomy experience?\n* Does tip control vary based on endoscopists' specialization?\n* Can training on the STSC model improve endoscopists' tip control?\n* Is it feasible to train an AI model using videos scored by expert raters to assess tip control?\n* Can tip control be used as an objective measure to predict endoscopists' future performance?\n\nResearch Hypothesis: The investigators hypothesize that developing a model for easy tip control assessment will enable endoscopists to evaluate their proficiency and track progress. Training on the STSC model will enhance tip control, and cut-offs for tip control derived from preliminary data will be refined through this study.",[60],"Evaluating Endoscopist Tip Control During STSC Application",[62,63,64,65,66],"endoscopic tip-control","snare tip soft coagulation (STSC) training model","Ham study endoscopy training","endoscopy STSC tip control","Ham study endoscopy tip control","2026-05-20",{"date":69,"type":36},"2026-05-27",{"date":71,"type":36},"2024-01-08",{"date":73,"type":21},"2027-06-30",{"name":42,"class":43},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":44},"100640453","paracetamol-and-cefazolin-pharmacokinetics-in-normal-weight-and-overweight-children-100640453","NCT07585487","Paracetamol and Cefazolin Pharmacokinetics in Normal Weight and Overweight Children","TISSUE","Inclusion Criteria:\n\n* Patient admitted to the operating room for minor elective surgery\n* Patients undergoing general anesthesia for minor elective surgery\n* Patient age: children from 2 years to 15 years\n* Patients receiving cefazolin or paracetamol according to the standard procedure\n* Intra-arterial (preferred) or intravenous access available for blood sampling\n* BMI\n\nExclusion Criteria:\n\n* Personal or family history of excessive bleeding\n* Pre-existing coagulopathy and\u002For thrombocytopenia\n* No catheter available for blood sampling\n* Absence of parental consent\n* Known allergy to one of the components of the study\n* Pregnancy","2 Years","15 Years",{"count":85,"type":21},120,"Pharmacokinetic evaluations will be conducted to characterize the cefazolin plasma concentration-time profile, cefazolin penetration into subcutaneous adipose tissue, and paracetamol metabolization as assessed through blood sampling. The study population consists of children aged 2 to 15 years with either normal weight or overweight. All participants are admitted for a minor elective surgical procedure and will receive paracetamol and\u002For cefazolin as part of standard perioperative care.\n\nDuring the procedure, multiple blood and tissue-fluid samples will be collected to quantify paracetamol and cefazolin concentrations in the bloodstream, as well as cefazolin concentrations in subcutaneous adipose tissue. The study aims to characterize drug concentration-time profiles in blood (paracetamol), plasma (cefazolin), and adipose tissue (cefazolin), and to compare these pharmacokinetic parameters between normal-weight and overweight children.\n\nThese data are essential to determine whether standard dosing regimens provide adequate drug exposure across different weight categories. Previous research indicates that achieving specific target concentrations in blood and tissue is necessary for optimal therapeutic effect, yet uncertainty remains regarding appropriate dosing in overweight children.",[88,89],"Paracetamol","Cefazolin",[88,89,91,92],"Overweight","children","2026-05-08",{"date":95,"type":36},"2026-05-13",{"date":97,"type":36},"2023-12-22",{"date":99,"type":21},"2027-01-30",{"name":42,"class":43},{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":44},"100561313","patient-specific-planning-of-minimally-invasive-brain-interventions-based-on-vascular-hemodynamic-mapping-100561313","NCT06588543","Patient-specific Planning of Minimally Invasive Brain Interventions Based on Vascular-hemodynamic Mapping","Inclusion Criteria:\n\n* Subjects who are diagnosed with aneurysm or arteriovenous malformation\n* Subjects who are treated (or will be treated) with endovascular embolization and\u002For arteriovenous coiling\n* During and before\u002Fafter the subject's intervention, medical images (MRI, 3D rotational angiography, DSA) were collected of the cerebral arterial vascular tree (which can be used to develop patient-specific models), including catheter location and use of contrast fluid to visualize the cerebral to make the arterial tree more visible.\n\nExclusion Criteria:\n\n-Procedures during which no imaging was performed",{"count":108,"type":21},500,"Endovascular procedures for treating brain aneurysms and arteriovenous malformations (AVMs) are becoming increasingly popular due to their less invasive nature and lower risk of complications. However, they still face challenges such as difficult catheter navigation and incomplete embolization.\n\nThis study aims to improve the efficiency and safety of endovascular procedures by developing new preoperative planning methodologies. These methodologies involve mapping the cerebral vasculature and creating computational fluid dynamics (CFD) and artificial intelligence (AI) models to simulate blood flow. By using these models, interventional radiologists can better plan catheter navigation and predict embolization outcomes. This could lead to faster, more accurate procedures with reduced radiation exposure for patients.",[111,112],"Intracranial Aneurysm","Arteriovenous Malformations, Cerebral",{"date":95,"type":36},{"date":115,"type":36},"2024-08-13",{"date":117,"type":21},"2030-12-31",{"name":42,"class":43},{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":55,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":44},"100640413","development-of-a-new-simplified-tool-to-predict-lnpcps-histology-and-assess-the-risk-of-submucosal-invasive-cancer-the-colorectal-regular-irregular-score-100640413","NCT07584486","Development of a New Simplified Tool to Predict LNPCPs Histology and Assess the Risk of Submucosal Invasive Cancer. The Colorectal Regular-Irregular Score","CRIS","Inclusion Criteria:\n\n* Consenting Endoscopists of varying abilities and grades (endoscopist)\n* Endoscopists who did not previously encounter the score (endoscopist)\n* LNPCPs detected or referred for resection (patient)\n\nExclusion Criteria:\n\n* Endoscopist does not consent to inclusion (endoscopist)\n* Video of inadequate quality as per opinion of the principal investigator\n* Endoscopist does not undergo learning intervention (endoscopist)\n* Patient does not consent to data collection for the study (patient)",{"count":127,"type":21},764,[57],"Colorectal cancer (CRC) is the third most common malignancy worldwide and the second leading cause of cancer related death. It can be prevented by endoscopic detection and complete resection of colorectal polyps. The JNET (Japanese NBI Expert Team) classification is clinically useful to predict the histology of large non-pedunculated colorectal polyps (LNPCPs) using narrow-band imaging at endoscopy. Japanese experts can reliably predict histology including the presence and depth of submucosal invasive cancer (SMI) using JNET with accuracy \\>87%. On the other hand, the International Evaluation of Endoscopy classification-JNET (IEE-JNET) group demonstrated that ESGE and JGES endoscopists had sufficient accuracy for JNET 1 (93.0%) but insufficient accuracy for JNET 2A\u002FB and 3 (respectively 62.1%, 55.1% and 85.1%). Reliably distinguishing between JNET 2A, 2B and 3 has a profound clinical relevance, since JNET 2A lesions can safely be resected using pEMR whereas JNET 2B lesions should be resected en-bloc (EMR or ESD) due to the increased risk of cancer and JNET 3 lesions are preferably treated with surgery due to the high risk of deeply invasive carcinoma and the necessity of lymph node resection.\n\nThis study aims to validate a new simplified score, the Colorectal Regular-Irregular Score (CRIS) to fulfill the urgent need for a more effective and easier to use tool to predict LNPCPs histology. CRIS is a simplification of the JNET score which is mainly used by Japanese endoscopists or experts, recent evidence suggests its accuracy when used in everyday endoscopy in the Western world is insufficient. The investigators aim to compare JNET with CRIS for LNPCPs histology prediction amongst Western endoscopists using both original JNET interpretation and a clinically relevant approach.\n\nThe study consists of three work packages (WPs):\n\nWork package one involves an expert online study where twelve expert endoscopists will evaluate 32 high-quality images of colorectal polyps using both JNET and CRIS classifications. Work package two involves an image\u002Fvideo-based online study where non-expert participants will be randomly assigned to rate images and videos using either JNET or CRIS, with performance re-evaluated after three months. Work package three involves a clinical study in a live endoscopy environment where non-expert endoscopists will participate in a randomized controlled trial assessing 10 colorectal polyps using either JNET or CRIS.",[131],"Colorectal Cancer",[133,134,135,136],"Colorectal cancer","Endoscopic imaging","colorectal polyps","endoscopist","NOT_YET_RECRUITING","2026-05-07",{"date":95,"type":36},{"date":141,"type":21},"2026-07-01",{"date":143,"type":21},"2028-12-31",{"name":42,"class":43},{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":153,"targetDuration":155,"studyType":23,"phases":4,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":172},"100611191","percutaneous-thermo-ablation-for-the-treatment-of-benign-thyroid-nodules-100611191","NCT07237373","Percutaneous Thermo-ablation for the Treatment of Benign Thyroid Nodules","Percutaneous Thermo-ablation for the Treatment of Benign Thyroid Nodules: a Prospective Multicentric Study","BIRRO-TA","Inclusion Criteria:\n\n* \\> 18 years old\n* 'Eastern Cooperative Oncology Group' (ECOG) performance status of 0 or 1\n* Symptomatic benign thyroid nodules with compressive\u002Fcosmetic complaints OR autonomously functioning thyroid nodules with subclinical hyperthyreosis or thyrotoxicosis proven on scintigraphy.\n* No cutoff in nodule size.\n* Solid component \\> 20%, and benign cytology (Bethesda II) in 1 (EUTIRADS 3) or 2 (EUTIRADS 4) separate cytological assessments. In the case of a proven \"hot\" nodule on scintigraphy, no biopsy is required.\n\nExclusion Criteria:\n\n* \\\u003C18y\n* Purely cystic nodule\n* Severe comorbidity which limits the further life expectancy of the patient to \\\u003C 2 years (opinion of the physician)\n* Malignancies \\\u003C2 years ago except for non-melanoma skin cancer and non-muscle invasive bladder cancer.\n* Lack of compliance\n* Malignant or suspicious thyroid nodules or nodules that are confluent in a compressive lobar mass\n* Contralateral vocal cord paralysis\n* Anticoagulant therapy that could not be suspended\n* Unresolvable coagulation disorders\n* Absence of consent of the patient",{"count":154,"type":21},50,"12 Months","The goal of this observational study is to learn if radiofrequency ablation (RFA), a minimally invasive thermoablation technique, can safely reduce symptoms and improve quality of life in adults with symptomatic benign thyroid nodules or autonomously functioning thyroid nodules.\n\nThe main questions it aims to answer are:\n\n* Does RFA improve health-related quality of life (HRQoL) as measured by the ThyPRO-39 questionnaire?\n* Does RFA effectively reduce nodule volume and related symptoms (compressive or cosmetic)?\n\nParticipants will:\n\n* Undergo a radiofrequency ablation procedure of the thyroid nodule performed under ultrasound guidance in an outpatient setting.\n* Complete quality of life questionnaires (ThyPRO-39) before treatment and at follow-up visits.\n\nAttend follow-up visits at 1, 3, 6, and 12 months with:\n\n* Ultrasound assessments of the thyroid nodule\n* Symptom and cosmetic scoring\n* Blood tests to monitor thyroid function\n* Safety checks for possible complications",[158],"Benign Thyroid Nodule",[160,161,162,163],"benign thyroid nodule","radiofrequency ablation","interventional radiology","percutaneous thermoablation","2026-04-23",{"date":166,"type":36},"2026-04-29",{"date":168,"type":36},"2026-03-03",{"date":170,"type":21},"2031-04-01",{"name":42,"class":43},3,{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":55,"phases":183,"briefSummary":184,"conditions":185,"keywords":188,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":205},"100623855","implementation-and-evaluation-of-a-program-aimed-at-facilitating-palliative-care-conversations-100623855","NCT07402057","Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations","Implementation and Evaluation of \"My Care My Voice\": a Program Aimed at Facilitating Conversations About Topics Such as Palliative Care","MCMV","Inclusion Criteria (physician):\n\n* Oncologist (medical oncologist, radiation oncologist, etc.), radiologist, organ specialist, nuclear medicine physician, ASO\n* The physician regularly interacts with people with advanced cancer\n* The physician is employed in an oncology hospital department\n\nExclusion Criteria (physician):\n\n* The physician works mostly (\\>50% of the time) in a hospital not involved in this study\n\nInclusion Criteria (healthcare provider - potential implementer):\n\n* Healthcare provider (e.g., study coordinator, oncology coach) or another hospital staff member (e.g., administrative staff)\n* The implementer regularly interacts with people with advanced cancer\n\nExclusion criteria (healthcare provider - potential implementer):\n\n\\- Physician participating in My Care, My Voice\n\nInclusion Criteria (patient):\n\n* The participant is an adult (18 years or older)\n* The participant has been diagnosed with advanced (i.e., non-curable) cancer (no curative treatment ongoing or planned). Participants receiving life-prolonging treatment are included.\n* The participant is aware of their diagnosis and treatment options as determined by their physician\n* The participant has known their initial diagnosis for more than one month\n* The participant is able to participate in a Dutch-language study\n* The participant is competent and able to voluntarily consent to participate in this study\n* The participant is hospitalized or receiving outpatient care\n\nExclusion Criteria (patient):\n\n* Estimated survival prognosis by the physician is longer than 5 years\n* The participant is in a follow-up trajectory or in remission according to the physician\n* The participant is already receiving specialized palliative care known to the treating physician",{"count":182,"type":21},271,[57],"Cancer is one of the leading causes of death worldwide. In the care of people with cancer, it is essential to pay sufficient attention to individual care needs and quality of life. One component of non-cancer-directed care, care aimed at addressing symptoms independent of the cancer or tumor, may be palliative care. Palliative care can be initiated at any point along the disease trajectory and can therefore be provided simultaneously with tumor-directed care. When initiated in a timely manner, palliative care can significantly improve the quality of life of both the person living with a life-threatening condition and their family. Pain management and attention to physical, psychosocial, and spiritual needs are central to this approach. Research shows that people with cancer develop palliative care needs well before the terminal phase. Communication about care needs, and palliative care in particular, is therefore essential for the timely initiation of palliative care.\n\nHowever, to date, palliative care is often initiated too late or not at all, frequently resulting in suboptimal care during the final months of life. Communication about palliative care is postponed or avoided by both healthcare professionals and people with cancer. Efforts are being made at various levels to make palliative care more discussable and to initiate it in a timely manner. At present, however, these efforts primarily focus on the role of healthcare services and professionals. By focusing solely on healthcare providers, palliative care has not yet been fully integrated as a standard component of oncological practice. The literature indicates that, in addition to barriers, there are also opportunities at the level of the person with cancer when it comes to initiating a conversation about palliative care with their physician, provided that adequate support is available.\n\nThe health promotion approach, which focuses on the role of various personal and environmental factors in stimulating healthy behavior, is well suited to addressing this need for change in patient-initiated communication about palliative care. Health promotion makes use of theoretical behavioral models, for which evidence demonstrates that their application leads to more effective behavioral interventions and successful behavior change. These models have also been shown to be promising in promoting behaviors related to palliative care and in enhancing patient empowerment.",[186,187],"Oncologic Diseases","Cancer",[189,190,187,191,192,193,194,195,196],"Palliative Care","Early palliative care","Oncology","Patient-physician communication","Patient empowerment","Health promotion","Behavioral change","Quality of life","2026-04-09",{"date":199,"type":36},"2026-04-14",{"date":201,"type":36},"2026-03-17",{"date":203,"type":21},"2026-12-31",{"name":42,"class":43},4,{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":55,"phases":216,"briefSummary":217,"conditions":218,"keywords":226,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":44},"100618117","coaching-doctors-and-nurses-to-improve-ethical-decision-making-in-team-100618117","NCT07327450","Coaching Doctors and Nurses to Improve Ethical Decision-making in Team","Coaching Doctors and Nurses to Improve Ethical Decision-making in Team: a Stepped Wedge Cluster Randomized Trial in 10 Departments of the Ghent University Hospital","CODE II","Inclusion Criteria:\n\n* Patients potentially receiving excessive treatment (PET) who are identified by clinicians during their first hospitalization. PET is defined as a patient in whom 2 or more clinicians doubt whether the treatment or treatment limitation code is consistent with their expected survival or quality of life (= \"too much\" or \"excessive treatment\") or whether the treatment limitation code is in line with the patient's or relatives' goals.\n* Family members of PET\n* Junior and senior doctors (including Department Heads) taking care of hospitalized patients\n* Nurses (including head nurses) taking care of hospitalized patients\n* Allied health professionals (psychologists, physical therapists, speech therapists, occupational therapists, social workers, spiritual care providers) taking care of hospitalized patients\n* PET admitted \u002F clinicians working in the 10 participating departments of of the Ghent University Hospital (Cardiology, Gastro-enterology and Hepatology, General Internal Medicine, Geriatrics, Hematology, Medical Oncology, Neurology, Nephrology (including dialysis unit), Pulmonology and the Medical ICU)\n\nExclusion Criteria:\n\n* PET with a previous written DNI-DNACPR order\n* Patients and family members of PET who are less than 18 years old and persons who cannot understand Ducth questionnaires",{"count":215,"type":21},360,[57],"Literature and a pilot study performed in 2019 indicate room for enhancing openness to discuss ethical sensitive issues within and between teams, and improving goal-oriented care and decision-making for the benefit of the patient at end-of-life, worldwide and more specifically in Belgium and in the Ghent University Hospital. The CODE study intervention performed in 2021 suggests already an improvement in goal oriented care operationalized via written Do-Not-Intubate and Do-Not-Attempt Cardio-Pulmonary Resuscitation (DNI-DNACPR orders in the Ghent University Hospital. In this study, the investigators found a nearly doubling of the incidence in written DNI-DNACPR in patient potentially receiving excessive treatment (PET) (from 19.7% to 29.7%, p\\\u003C0.001) and in patients hospitalized for the first time (from 1.9% to 3.4%, p=0.011) without increasing one-year mortality, after coaching doctors during 4 months in self-reflective and empowering leadership, and coping with group dynamics. However, the investigators found no improvement in the perception of the quality of the ethical climate by clinicians, more specifically by nurses. Despite the fact that ethical decision-making is considered a strategic priority in the Ghent University Hospital and an intense communication campaign, clinicians identified also a much smaller number of PET during this interventional study than during the observational pilot study in 2019. Although fading attention for the study over time and visibility of the electronic CODE alert to identify PET was claimed as the main reasons by 75% and 50.7% of the nurses, respectively, 95% expressed the desire to keep on using this alert in the future. This underscores a deeper concern in nurses. More than 40% expressed fear of blaming doctors or skepticism regarding the impact of identifying PET. Nonetheless, 35% acknowledged improvement in interdisciplinary meetings about end-of-life issues since study initiation. These findings highlights the need to additionally coach the entire team in future studies. Indeed, creating a safe climate which enhances inter-professional shared decision-making for the benefit of the patient requires both, specific self-reflective and empowering leadership skills in doctors and head nurses (including the management of group dynamics in the interdisciplinary team), and confidence in speaking up in nurses and other health care professionals. This is what the investigators want to develop with this intervention. These skills will also help clinicians during patient and family meetings which will enable clinicians to better take into account the patient's and family's wishes.",[219,220,221,222,223,224,225],"Decision Making ,Shared","Leadership","End of Life Communication","End of Life Decision Making","End of Life Patients","Ethical Sensitivities","Coaching",[225,227,228,229,230,231,232],"Shared decision-making","Goal-oriented care","Ethical climate","Leaderschip","Communication","End-of-life","2026-04-03",{"date":197,"type":36},{"date":236,"type":21},"2026-04-01",{"date":238,"type":21},"2028-06-30",{"name":42,"class":43},{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":247,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":249,"conditions":250,"keywords":253,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":44},"100632444","emotion-regulation-in-rnt-100632444","NCT07513766","Emotion Regulation in RNT","The Neural Mechanisms of Emotion Dysregulation in Repetitive Negative Thinking (RNT) Patients: A Pilot Study","Inclusion Criteria:\n\n* Patient group: diagnosis of depression\u002FGAD\n* Healthy control group: no history of or current form of psychopathology",{"count":248,"type":21},100,"The goal of this study is to understand why some people become stuck in repetitive negative thinking, which is common among individuals with depression and anxiety. Repetitive negative thinking involves repeatedly focusing on negative events, worries, or problems. These thoughts can be difficult to control and may worsen emotional distress and daily functioning.\n\nResearchers believe that repetitive negative thinking may be related to changes in how different brain networks communicate with each other. This study will examine how the brain responds during emotion regulation tasks in people who tend to ruminate compared with healthy individuals.\n\nTo do this, researchers will use a brain-imaging technique called functional near-infrared spectroscopy (fNIRS). This method measures brain activity using harmless infrared light while participants perform tasks on a computer.\n\nThe main questions this study aims to answer are:\n\nHow does the brain respond to emotional situations in people who experience repetitive negative thinking?\n\nAre there differences in brain activity between people with depression or anxiety and healthy individuals during emotion regulation?\n\nParticipants will include 50 healthy volunteers and 50 individuals with depression or anxiety who experience repetitive negative thinking.\n\nParticipants will:\n\nWear a lightweight brain-imaging device (fNIRS) placed on the head to measure brain activity\n\nComplete computer tasks involving emotional images and different emotion-regulation strategies, such as reinterpreting, suppressing, or distracting from emotions\n\nListen to different types of spoken feedback (criticism, praise, or neutral comments) and imagine receiving them from someone they know\n\nReport their emotional feelings during the tasks\n\nComplete several questionnaires about mood, thinking patterns, and emotional experiences\n\nDuring the experiment, researchers will also record physiological responses such as heart activity and skin reactions, which are related to emotional responses.\n\nThe results of this study may help researchers better understand the brain mechanisms underlying rumination and may contribute to the development of more effective treatments for depression and anxiety.",[251,252],"Repetitive Negative Thinking","Healthy Controls Group - Age and Sex-matched",[254,255,256],"Repetitive negative thinking","fnirs","emotion regulation","2026-03-30",{"date":259,"type":36},"2026-04-07",{"date":261,"type":36},"2024-06-05",{"date":263,"type":21},"2026-12-30",{"name":42,"class":43},{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":51,"sex":17,"minAge":272,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":275,"conditions":276,"keywords":278,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":289},"100578387","polyphenol-metabotypes-in-people-with-diabetes-type-2-100578387","NCT06810635","Polyphenol Metabotypes in People With Diabetes Type 2","PPPIL","Inclusion Criteria:\n\n* all participants\n* between 40-85 years\n* age-matched individuals without diabetes\n* BMI between 18.5-30\n* no metabolic syndrome\n* persons with T2DM\n* at leats 2 years of clinical diagnoses of T2DM\n* stable medication use for at least 1 month\n\nExclusion Criteria:\n\n* pregnancy of breastfeeding\n* in last month\n* acute use of anti\u002Fpre\u002Fprobiotics\n* start of new drug or dietary supplements\n* major changes in diet\n* major lifestyle changes\n* diseases\n* Gastrointestinal diseases (inflammatory bowel disease)\n* Bariatric surgery\n* Other forms of diabetes (cystic fibrosis\u002FMODY\u002FT1DM)\n* Heart problems (NYHA 3\u002F4) or previous cardiovascular events\n* Liver problems: non-alcohol steatohepatitis (NASH) and cirrhosis\n* Lung problems (COPD - GOLD 3\u002F4), cystic fibrosis\n* Uncontrolled thyroid function disruption in the past 6 months\n* Intake of coumarin derivatives and direct oral anticoagulant medication\n* Anti-cancer treatment: chemo-\u002Fimmunotherapy\n* Immonosuppressants (transplant)\n* Antiepileptic drugs","40 Years","85 Years",{"count":248,"type":21},"This cross-sectional study seeks to characterize the overall polyphenol metabotype in patients with T2DM in comparison to age-matched individuals without diabetes. Additionally, the study aims to identify factors that influence the polyphenol metabotype (transit time and gut microbial capacity to degrade polyphenols in particular).",[277],"Type 2 Diabetes Mellitus (T2DM)",[279,280],"polyphenol","transit time","2026-03-19",{"date":283,"type":36},"2026-03-23",{"date":285,"type":36},"2026-03-04",{"date":287,"type":21},"2028-12",{"name":42,"class":43},2,{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":296,"targetDuration":4,"studyType":55,"phases":298,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":44},"100629711","an-interventional-study-to-evaluate-the-impact-of-blood-flow-restriction-training-on-muscle-bone-and-quality-of-life-in-adults-with-osteogenesis-imperfecta-type-i-100629711","NCT07478224","An Interventional Study to Evaluate the Impact of Blood Flow Restriction Training on Muscle, Bone, and Quality of Life in Adults With Osteogenesis Imperfecta Type I","Inclusion Criteria:\n\n* Osteogenesis imperfecta type I, aged between 18 and 65 years old\n\nExclusion Criteria:\n\n* Lower limbs:\n\nEdema; Recent surgery; Acute fractures\n\n* Pregnancy\u002F\\\u003C6 months postpartum\n* Deep vein thrombosis (now or history of)\n* Cardiovascular, respiratory, or neuromuscular diseases\n* Recent cardiovascular events\u002Funtreated hypertension\n* Diseases affecting vascular function (e.g., diabetes)\n* Vigorous strength training in year before study\n* Other contraindications to perform exercise",{"count":297,"type":21},40,[57],"Background: Due to fear of injury and risk of fractures, many people with osteogenesis imperfecta (OI) avoid vigorous exercise that is likely to improve muscle and bone weakness common in this disorder. Low-intensity muscle strength training with blood flow restriction (BFR-LI) via an inflatable cuff leads to similar improvements in muscle size and strength to conventional high-intensity strength training but has not been applied in OI.Objectives: To evaluate the effect of BFR-LI on muscle and bone health and quality of life in adults with OI type I.Methods: For this randomized controlled trial, 40 adults (18-65y) with OI type I will be recruited. Exclusion criteria include pregnancy or \\\u003C6 months postpartum, deep vein thrombosis, acute fractures, recent surgery, regular vigorous exercise, or contraindications to exercise. Participants will be randomly assigned to perform BFR-LI or standard care. The BFR-LI group will perform home-based exercises 2-3 times\u002Fweek for 12 weeks at low training intensity (20% of 1-repetition maximum) which will increase every 4 weeks. Muscle and bone parameters will be evaluated using scans (peripheral computed tomography and dual-energy x-ray absorptiometry) and muscle strength tests, and quality of life (mental well-being, participation, pain and fatigue) by the PROMIS questionnaire at baseline, immediately, three, and six months after training.",[301],"Osteogenesis Imperfecta, Type I",[303,304,305,306,307,196],"Blood flow restriction","Exercise","Osteogenesis Imperfecta","Muscle","Bone","2026-03-12",{"date":201,"type":36},{"date":311,"type":36},"2025-08-19",{"date":313,"type":21},"2026-12",{"name":42,"class":43},{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":55,"phases":325,"briefSummary":326,"conditions":327,"keywords":330,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":44},"100544488","combination-of-neurostimulation-and-psychotherapy-to-stop-worrying-100544488","NCT06369532","Combination of Neurostimulation and Psychotherapy to Stop Worrying","Stop Worrying, Learn to Let go Through a Combination of Neurostimulation and Psychotherapy","Inclusion Criteria:\n\n* Generalized anxiety disorder (GAD)\n* Depressive disorder\n\nExclusion Criteria:\n\n* other psychiatric pathology than GAD or depression screened by senior psychiatrist by means of the Mini-International Neuropsychiatric Interview (MINI) and psychiatric anamnesis\n* Abuse of alcohol, drugs or medication other than prescribed by general practitioner or psychiatrist\n* no consent to participate in measurement (questionnaire, fNIRS or EEG)\n* Insufficient knowledge of the current language (Dutch)\n* Acute or chronic suicidality\n* Acute psychosis or manic depressive disorder\n* Inability to commit to 8 sessions of Cognitive-Behavioral Therapy (CBT) or receive 4 weeks of transcranial Direct Current Stimulation (tDCS).","70 Years",{"count":324,"type":21},85,[57],"This study aims to investigate whether the combination of transcranial Direct Current Stimulation (tDCS) and cognitive-behavioral therapy (CBT) is more effective for treating repetitive negative thinking (RNT) in patients with the symptom of high rumination. High ruminators will be included (Group1, active tDCS-CBT group; Group2, sham tDCS-CBT group). All patients will receive active or sham tDCS.",[328,329],"Active tDCS","Sham tDCS",[331],"transcranial direct current stimulation","2026-03-11",{"date":308,"type":36},{"date":335,"type":36},"2024-03-06",{"date":337,"type":21},"2027-12-20",{"name":42,"class":43},{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":55,"phases":349,"briefSummary":351,"conditions":352,"keywords":354,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":364},"100546681","phase-4-proactive-tdm-versus-standard-use-of-biologics-in-psoriasis-100546681","NCT06398106","Proactive TDM Versus Standard Use of Biologics in Psoriasis","Proactive Therapeutic Drug Monitoring Versus Routine Care With the Novel Biologics in Psoriasis : a Pragmatic, Multicentric, Randomised, Controlled Study","HELIOS","Inclusion Criteria:\n\n1. Adults; aged 18 years or older\n2. Documented diagnosis of psoriasis (predominantly type vulgaris; based on clinical diagnosis) by an accredited dermatologist\n3. Patients must be currently treated with secukinumab, ixekizumab or guselkumab ≥ 6 months according to the standard dosing scheme.\n4. The subject signs and dates a written informed consent form and any required privacy authorization prior to the initiation of any study procedures\n\nExclusion Criteria:\n\n1. Another indication than plaque psoriasis as the main indication for biologic use (e.g. receives biologic for rheumatoid arthritis as the main indication)\n2. Concomitant use of systemic immunosuppressants other than methotrexate or acitretin (e.g. prednisone, cyclosporine etc)\n3. Severe comorbidities with short life-expectancy (e.g. metastasized tumour) or uncontrolled PsA at inclusion\u002Fbaseline\n4. Presumed inability to follow the study protocol\n5. Active pregnancy wish",{"count":348,"type":21},210,[350],"PHASE4","Biologics are effective agents for the treatment of psoriasis. The newest generation of biologics block interleukin 17 and 23. Physicians always prescribe these drugs in a fixed dose, but this may lead to under- and overdosing in some patients. Underdosing may lead to inadequate response or loss of response over time. Overdosage, on the other hand, can lead to higher risk of side effects and higher costs for the healthcare system. In daily clinical practice, physicians often tackle this real-world issue by blind trial- and- error dose modifications or switching to another biologic. In this study, we want to rationalize these dose modifications and optimize dosing based on the drug concentrations, measured in the blood of the patient (i.e. therapeutic drug monitoring). Depending on the drug concentration, the interval between injections will be lengthened or shortened with the aim to reach the required drug concentration to reach the best clinical result. The trial will be conducted in 14 Belgian hospitals where patients will be divided into 2 study groups: a group that will be advised on the dosing scheme of their biologic based on the measured drug concentration and a group that continues dosing as in daily clinical practice. We will monitor if the clinical response and quality of life remains stable. With this study, we will track drug concentrations as we believe that they can guide dosing of biologics and we hope to achieve better safety, lower healthcare expenses and higher patients' treatment satisfaction while striving for the best clinical response.",[353],"Psoriasis Vulgaris",[355,356],"Therapeutic drug monitoring","Biologics","2026-03-02",{"date":285,"type":36},{"date":360,"type":36},"2024-12-20",{"date":362,"type":21},"2028-03-01",{"name":42,"class":43},15,{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":374,"conditions":375,"keywords":379,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":44},"100626692","measurement-of-airway-opening-index-during-out-of-hospital-cardiac-arrest-the-lazarus-aoi-trial-100626692","NCT07438938","Measurement of Airway Opening Index During Out-of-hospital Cardiac Arrest: The Lazarus AOI Trial.","Lazarus-AOI","Inclusion Criteria:\n\n* Adult (over 18 years old) patients with out-of-hospital cardiac arrest.\n* Patients undergoing cardiopulmonary resuscitation (CPR).\n* Patients who were intubated and had available capnogram recordings immediately after intubation.\n\nExclusion Criteria:\n\n* Patients that were not intubated\n* Patients that did not receive CPR following intubation\n* Cases with a technical challenge with the ETCO₂ measurement (i.e., issues with waveform data of the capnogram.",{"count":373,"type":21},150,"Out-of-hospital cardiac arrest (OHCA) is a leading cause of death worldwide. Despite constantly improving resuscitation techniques, the chances of survival remain limited. During cardiopulmonary resuscitation (CPR), a closure of the airway may occur, impeding ventilation. This phenomenon also complicates the interpretation of the end-tidal CO2 (ETCO2) in the capnogram. The extent to which airway closure occurs is quantified by the Airway Opening Index (AOI). This can be calculated from the capnogram and is seen as a measure of the quality of CPR applied as well as a possible indicator to predict the outcome of CPR.\n\nIn this study, we analyse capnogram data from approximately 150 cases, collected during interventions for OHCA and logged in the Lazarus database (UZ Gent and AZORG) to answer three research questions below:\n\n1. What is the prevalence of AOI during CPR?\n2. Is there a correlation between AOI and return of spontaneous circulation (ROSC)?\n3. Does the application of positive end-expiratory pressure (PEEP) affect the AOI and ROSC?\n\nA mathematical model for calculating AOI, based on a method from previous work by Bandhari et al. \\[1\\] will be developed. Using this model, the AOI will be calculated from the individual capnograms for all cases in the Lazarus database.\n\nIn addition, a multivariable regression model will be used to analyse whether AOI can be used to predict ROSC. Corrections will be made for relevant confounders such as age, gender, witnessed arrest and rhythm pattern.\n\nFinally, it is investigated whether PEEP has a positive influence on AOI. This study aims to contribute to better insights into airway dynamics during CPR and the optimization of ventilation in OHCA.",[376,377,378],"Cardiac Arrest (CA)","Out-of-hospital Cardiac Arrest (OHCA)","Resuscitated Sudden Cardiac Death",[380,381],"capnography","airway closure","2026-02-23",{"date":384,"type":36},"2026-02-27",{"date":386,"type":36},"2022-10-01",{"date":388,"type":21},"2027-01-01",{"name":42,"class":43},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":55,"phases":399,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":412},"100449480","phase-2-use-of-beetroot-juice-to-protect-against-postoperative-ileus-following-colorectal-surgery-beet-it-study-100449480","NCT05133024","Use of Beetroot Juice to Protect Against Postoperative Ileus Following Colorectal Surgery: BEET IT Study","BEET IT","Inclusion Criteria:\n\n* Adult patients undergoing elective colonic and upper rectum laparoscopic surgery requiring an anastomosis, without the need of conversion\n\nExclusion Criteria:\n\nGeneral:\n\n* \\\u003C 18 years of age\n* Pregnancy or breast feeding\n\nMedical:\n\n* Psychiatric pathology capable of affecting comprehension and judgment faculty\n* History of inflammatory bowel disease\n* Chronic vascular disease affecting the intestines\n* Chronic constipation (\\\u003C= 2 bowel movements\u002Fweek)\n* Previous abdominal or pelvic radiation treatment\n* Recent (\\\u003C 3 months before inclusion) or current intra-abdominal infection or inflammation (e.g. diverticulitis, appendicitis, cholecystitis)\n* Use of gut motility influencing agents (e.g. tricyclic antidepressants, chronic use of laxatives)\n* Use of nitrates (e.g. isosorbide dinitrate, nitroglycerin), including daily consumption of beetroot juice (unless stopped for a month prior to the intervention period)\n* Hypotension (\\\u003C 100\u002F60 mmHg)\n* Uncontrolled diabetes mellitus\n* Renal or hepatic insufficiency\n* Known allergies or intolerances to beetroot, nitrates\u002Fnitrites\n* Enrollment in other clinical trials\u002Fexperiments, unless approved by the Ethics Committee(s)\n\nSurgical:\n\n* History of prior colorectal surgery\n* Emergency surgery\n* Open surgery\n* Colorectal surgery not requiring an anastomosis (e.g. colotomy, wedge resection)\n* More than 1 bowel anastomosis planned\n* Concomitant surgical procedures required (e.g. resection of liver or lung metastases)\n* Protective stoma planned",{"count":398,"type":21},170,[400],"PHASE2","The goal of the BEET IT study is to examine if preoperative intake of beetroot juice can ameliorate gastrointestinal (GI) recovery after colorectal surgery and thereby help to reduce the duration of postoperative ileus (POI) and prevent prolonged POI. Adult patients undergoing laparoscopic colorectal surgery are randomized 1:1 to consume either concentrated beetroot juice (active intervention) or nitrate-depleted concentrated beetroot juice (placebo) during the week before their surgery. Blood, tissue and\u002For fecal samples are collected at specific time points pre- and\u002For postoperatively to study markers related to inflammation, oxidative stress and GI function. Patients are followed from the week before surgery (start of the intervention) until 3 months post-surgery. The study takes place at 5 hospitals in Flanders, Belgium.",[403],"Postoperative Ileus","2026-02-06",{"date":406,"type":36},"2026-02-10",{"date":408,"type":36},"2021-03-31",{"date":410,"type":21},"2027-12-30",{"name":42,"class":43},6,{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":420,"targetDuration":4,"studyType":55,"phases":422,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":436},"100588279","phase-3-the-application-of-positive-end-expiratory-pressure-in-out-of-hospital-cardiac-arrest-the-lazarus-peep-trial-100588279","NCT06939335","The Application of Positive End-Expiratory Pressure in Out-of-Hospital Cardiac Arrest: The Lazarus-PEEP Trial.","Lazarus-PEEP","Inclusion Criteria:\n\n1. Age: Adults aged 18 years and older.\n2. Type of Cardiac Arrest: Patients who have experienced a non-traumatic out-of-hospital cardiac arrest.\n3. CPR Administration: Patients receiving cardiopulmonary resuscitation from an advanced life support (ALS) team.\n4. Intubation and Ventilation: Patients who are intubated and ventilated during resuscitation efforts.\n\nExclusion Criteria:\n\n1. Cardiac arrest in patient younger than 18 years of age.\n2. Traumatic cardiac arrest, including drowning, penetrating or blunt injury, and burns.\n3. Immediate Return of Spontaneous Circulation (ROSC): Patients who achieve ROSC before intubation and initiation of intubation.\n4. Pregnancy.\n5. Mechanical ventilation during arrest: patients already receiving mechanical ventilation at the moment of cardiac arrest, due to reasons other than their arrest, will be excluded.\n6. Do Not Resuscitate (DNR) Orders: Patients with existing DNR orders or any advanced directive indicating that CPR should not be performed.\n7. Failure to intubate: if intubation is unsuccessful, ventilation by any means (MBV, SGA) should take priority over the study protocol, and the patient is excluded.\n8. Enrolment in Other Studies: Patients currently enrolled in another interventional clinical trial that could interfere with the outcomes of this study.",{"count":421,"type":21},132,[423],"PHASE3","The goal of this clinical trial is to learn whether using Positive End-Expiratory Pressure (PEEP) during cardiopulmonary resuscitation (CPR) improves outcomes for adults who experience out-of-hospital cardiac arrest, a condition where the heart suddenly stops beating. PEEP is used during ventilation, which may enhance oxygen levels by keeping the airways open throughout CPR.\n\nThis study aims to determine if using PEEP during CPR helps restart the heart more effectively, improves survival rates, and enhances survival with good neurologic outcomes after a cardiac arrest compared to standard CPR without PEEP.\n\nResearchers will randomly assign participants to one of two groups: one receiving CPR with PEEP set at 5 cm of water pressure and the other receiving standard CPR without PEEP. Participants will be treated by emergency medical teams trained in advanced life support, and specialised sensors will measure airflow and airway pressure during resuscitation.\n\nAdditionally, the study will evaluate potential side effects associated with PEEP, such as increased pressure within the chest or lung injuries. Findings from this trial will guide recommendations on the usage of PEEP in standard CPR practices to potentially improve patient outcomes.",[376,377,426,427],"Positive End-expiratory Pressure (PEEP)","Ventilation During Resuscitation","2026-01-20",{"date":430,"type":36},"2026-01-21",{"date":432,"type":36},"2025-04-25",{"date":434,"type":21},"2027-02-01",{"name":42,"class":43},7,{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":445,"minAge":18,"maxAge":272,"enrollmentInfo":446,"targetDuration":4,"studyType":55,"phases":448,"briefSummary":449,"conditions":450,"keywords":452,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":44},"100620598","a-prospective-study-to-evaluate-the-outcome-of-the-aurora-test-used-with-blastocyst-transfer-in-an-icsi-cycle-aurora-blasto-100620598","NCT07359703","A Prospective Study to Evaluate the Outcome of the Aurora Test Used With Blastocyst Transfer in an ICSI Cycle (Aurora-Blasto)","A Prospective Study to Evaluate the Outcome of the Aurora Test Used With Blastocyst Transfer in an ICSI Cycle","Aurora-Blasto","Inclusion Criteria:\n\n1. Patients undergoing ICSI treatment, with maximum 40 years of age at time of signing the ICF\n2. Patients stimulated with GnRH antagonist\u002FHP-hMG or GnRH antagonist\u002FrecFSH, scheduled for fresh SET Day 5 with hCG or dual trigger (hCG + GnRH agonist) or Patients stimulated with GnRH antagonist\u002FHP-hMG or GnRH antagonist\u002FrecFSH, scheduled for delayed transfer of frozen\u002Fthawed SET Day 5 after a GnRH agonist trigger, hCG or dual trigger (hCG + GnRH agonist).\n3. Patients undergoing a first, second, third or fourth ICSI cycle\n4. Women with body mass index (BMI) higher than 17 and lower than 35\n5. Women with regular cycles (between 24 and 35 days)\n6. Non-and mild-smokers (\\\u003C10 cigarettes\u002Fday)\n7. AMH 1,1 ng\u002Fml (Bologna criteria), excluding poor responders according to Bologna criteria\n8. Patients with fresh ejaculated semen or frozen donor semen\n\nExclusion Criteria:\n\n1. Patients with less than 8 follicles (≥12mm) on the day of their last echo visit before OPU.\n2. Women with history of poor oocyte maturation in a previous cycle (\\\u003C 50% MII)\n3. Women with Severe Endometriosis (≥ III AFS classification) (in the ovaries and if not surgically treated)\n4. Patients scheduled for PGD (preimplantation genetic diagnosis of monogenic\u002Fsingle gene defects) and PGT-A (preimplantation genetic testing on aneuploidy)\n5. Couples where the partner has an extremely low sperm count e.g.: severe oligo-astheno-teratozoospermia (OAT) with sperm count below 100.000\u002Fml or TESE.","FEMALE",{"count":447,"type":21},1028,[57],"In current treatments for In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI), the creation of multiple embryos is a common practice. The decision to transfer an embryo is traditionally based on the morphological assessment by an embryologist, which, due to its nature, must be considered subjective. In certain regions, invasive embryo biopsy techniques, such as Preimplantation Genetic Testing for Aneuploidy (PGT-A), are used to detect chromosomal abnormalities and support decision-making regarding embryo transfer. However, there is a medical need to improve the outcomes of IVF\u002FICSI cycles through non-invasive and objective methods.\n\nAs an academic center, our goal is to investigate promising innovative methods that, if successful, can be integrated into standard care. The aim of the Aurora blastocyst study is to evaluate the effectiveness of the Aurora test in selecting five-day-old embryos for fresh or frozen embryo transfer. Additionally, the study assesses whether the use of the Aurora test results in an increase in clinical pregnancy rates and live birth rates.\n\nThe Aurora test is a non-invasive test for evaluating oocyte competence and subsequently the embryo obtained in an ICSI cycle (In Vitro Fertilization). This test is performed on cumulus cells (CC) surrounding the oocyte and uses mRNA expression profiles to evaluate the developmental potential of the oocytes. The test has been developed and validated for patients stimulated with human menopausal gonadotropins (HP-hMG), an ovulatory dose of hCG, and a single embryo transfer on day 3. The test will be performed by Fertiga nv, upon receiving patients cumulus cells.\n\nAt our center, based on earlier research, the standard care involves a single embryo transfer on day 5. In this study, embryo selection based on morphology is compared with embryo selection based on morphology and the Aurora test. Finally, this study aims to evaluate the impact of the Aurora test score on the embryologist's selection decision for transferring a five-day-old embryo for single embryo transfer, by assessing parameters such as pregnancy rates and live birth rates.",[451],"Infertility Assisted Reproductive Technology",[453],"ART","2026-01-15",{"date":456,"type":36},"2026-01-22",{"date":458,"type":36},"2025-10-15",{"date":460,"type":21},"2029-06-01",{"name":42,"class":43},{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":83,"enrollmentInfo":470,"targetDuration":4,"studyType":55,"phases":472,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":488,"locationsCount":172},"100548887","pediatric-antibiotic-dosing-in-extracorporal-membrane-oxygenation-padecmo-100548887","NCT06426836","Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)","Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation","PADECMO","Inclusion Criteria:\n\n* patients admitted to the pediatric intensive care unit or cardiac intensive care unit\n* patient age : 1,8 kg-15 years\n* patient receiving antibiotic treatment (piperacillin-tazobactam, meropenem, amoxicillin-clavulanate, cephazolin, vancomycin, teicoplanin, ciprofloxacin, amikacin)\n* intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)\n* extracorporeal membrane oxygenation circuit\n\nExclusion Criteria:\n\n* no catheter in place for blood sampling\n* absence of parental\u002Fpatient consent\n* known hypersensitivity to beta-lactam antibiotics and ciprofloxacin",{"count":471,"type":21},300,[57],"Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO).",[475,476,477,478,89,479,480,481,482],"Pharmacokinetics","Amoxicillin-clavulanate","Piperacillin-tazobactam","Meropenem","Teicoplanin","Vancomycin","Ciprofloxacin","Amikacin",{"date":484,"type":36},"2026-01-16",{"date":486,"type":36},"2016-08-19",{"date":141,"type":21},{"name":42,"class":43},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":17,"minAge":22,"maxAge":496,"enrollmentInfo":497,"targetDuration":499,"studyType":23,"phases":4,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":44},"100244176","antibiotic-dosing-in-pediatric-intensive-care-100244176","NCT02456974","Antibiotic Dosing in Pediatric Intensive Care","ADIC","Inclusion Criteria:\n\n* patients admitted to the pediatric intensive care unit\n* patient age\u002Fweight : 1,8 kg-15 years\n* patient receiving antibiotic treatment (piperacillin-tazobactam, amoxicillin-clavulanate, vancomycin, teicoplanin, meropenem, ciprofloxacin, amikacin) via intermittent infusion regimen or continuous infusion according to institutional treatment guidelines\n* intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)\n\nExclusion Criteria:\n\n* no catheter in place for blood sampling\n* absence of parental\u002Fpatient consent\n* known hypersensitivity to beta-lactam antibiotics, glycopeptides, fluoroquinolones, aminoglycosides\n* extracorporeal circuit (haemodialysis, ECMO, peritoneal dialysis )","16 Years",{"count":498,"type":21},640,"3 Days","Pharmacokinetics of antibiotics in critically ill neonates, infants and children",[475,476,477,480,479,478,481,482],{"date":484,"type":36},{"date":504,"type":4},"2012-05",{"date":506,"type":21},"2027-09-01",{"name":42,"class":43},{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":445,"minAge":18,"maxAge":516,"enrollmentInfo":517,"targetDuration":4,"studyType":55,"phases":518,"briefSummary":519,"conditions":520,"keywords":522,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":4},"100617209","pain-associated-with-traditional-versus-ultrasound-guided-ius-intra-uterine-system-insertion-100617209","NCT07315646","Pain Associated wIth traditioNal Versus uLtrasound guidEd iuS (Intra Uterine System) inSertion","The PAINLESS Study: Pain Associated wIth traditioNal Versus uLtrasound guidEd iuS (Intra Uterine System) inSertion","PAINLESS","Inclusion Criteria:\n\n* Women between18 years and 60 years (at the time of signing the ICF)\n* Who wish to have an IUS (Kyleena\u002FMirena) for reasons of family planning, conservative treatment for abnormal uterine bleeding or as part of hormonal treatment for menopausal symptoms\n* Dutch-speaking subjects\n\nExclusion Criteria:\n\n* History of difficult IUS placement\n* Known cervical stenosis\n* Asherman's syndrome\n* Standard contraindications to an IUS (eg breast cancer, recent deep vein thrombosis, anatomical uterine abnormalities, pregnancy, acute PID, cervicitis, vaginitis or any lower genital tract infection, cervical or endometrial malignancy, history of septic abortion or postpartum endometritis in the last 3 months,.. )\n* Current pelvic inflammatory disease\n* Pregnancy\n* Trophoblastic disease\n* Known cervical or endometrial carcinoma\n* Patients who have the profession of midwife, nurse or doctor.","60 Years",{"count":154,"type":21},[57],"Rationale: The 2019 Belgian Health Survey shows that the combined oral contraceptive pill is the most commonly used form of contraception. However, the Pearl index of Long-acting reversible contraceptive (LARC) methods is significantly better (perfect and typical use \\\u003C0.5) compared to the combined oral contraceptive pill (perfect use \\\u003C1.0, typical use 2-9). An IUS is an example of a LARC method. IUS insertion might be painful. Because of this, women may be reluctant to opt for an IUS. The traditional technique for an IUS insertion uses a speculum after which a Pozzi tenaculum is placed on the cervix so that the uterus is brought into the stretching position by means of traction. The cavum is then measured by a uterine sound. These actions and the use of these instruments can contribute to the pain experience during insertion. The new technique, transabdominal sonographic (TAS) insertion, could reduce the pain experience during insertion. This new technique uses transabdominal sonography during IUS placement. The placement under constant visualization eliminates the need for Pozzi tenaculum and uterine soundings. Little high quality studies have been conducted on the advantages and disadvantages of the TAS technique as demonstrated by a non-published systematic review of the literature.\n\nResearch question\u002Fgoal: Is the insertion of an IUS (Kyleena\u002FMirena) using the TAS technique less painful than the traditional technique?\n\nStudy design: A randomized trial (RCT) in which the subject is blinded to the insertion technique.\n\nStudy population: Women wishing an IUS (Kyleena \\& Mirena)\n\nPrimary and secondary outcomes:\n\nThe primary outcomes are the pain during insertion (Numeric Rating Scale (NRS) score 0-10) and dislocation: non-fundal position (\\> 3mm fundal distance postinsertion) in the uterine cavity (Y\u002FN).\n\nSecondary outcomes include the average and worst pain in the first week after insertion (NRS 0-10), expulsion of the IUS, perforation of the uterine wall, failure of insertion, the occurrence of vagal symptoms, use of pain relief the first 7 days after placement, subject satisfaction about the procedure, successful IUS placement.",[521],"Intra-uterine Device Placement",[523,524,525,526,527,528],"intra-uterine device placement","TAS-technique","contraception use","uterine bleeding heavy","menopausal bleeding","family planning","2026-01-02",{"date":531,"type":36},"2026-01-07",{"date":533,"type":21},"2025-12-18",{"date":535,"type":21},"2027-12-31",{"name":42,"class":43},{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":545,"conditions":546,"keywords":550,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":557,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":561,"locationsCount":44},"100617208","an-innovative-cfd-based-dosimetry-and-pre-treatment-planning-platform-to-support-personalized-transarterial-therapies-for-liver-cancer-100617208","NCT07315633","An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies for Liver Cancer","Inclusion Criteria:\n\n* Subjects radiologically diagnosed with HCC, eligible for or undergoing treatment.\n* Subjects who are treated (or will be treated) using TARE with radioactive microspheres.\n* Subjects for whom pre-treatment medical imaging of the hepatic arterial vasculature was performed for TARE planning (e.g., CT, MRI, PET, SPECT, and DSA), which can be used to develop patient-specific 3D models of the hepatic arterial tree and treatment dose distribution.\n\nExclusion Criteria:\n\n* Subjects undergoing TARE procedures without adequate medical imaging of the hepatic vasculature.\n* Subjects in whom no pre- or post-treatment imaging data are available for analysis.",{"count":544,"type":21},80,"Transarterial radioembolization (TARE) is a key treatment option for patients with unresectable hepatocellular carcinoma (HCC), a primary form of liver cancer. TARE is a minimally invasive therapy in which radioactive microspheres are delivered through a microcatheter near the tumour into the liver's blood vessels. Although TARE can significantly improve survival, treatment outcomes remain variable and difficult to predict, mainly because of complex liver vasculature and unpredictable distribution of radioactive microspheres due to uncertain parameters such as catheter tip location, catheter orientation, and injection velocity.\n\nThe long-term goal would be to make these treatments more predictable and effective by developing a patient-specific pre-treatment planning platform. Blood flow and microsphere transport will be modelled in a digital model of the patient-specific hepatic arterial tree (based on clinical imaging) using computational fluid dynamics (CFD), in combination with Monte Carlo-based radiation dosimetry. Using CFD simulations, we will investigate how variations in treatment parameters influence the microsphere distribution, aiming to better understand their role in treatment variability. This will allow us to predict the dose distribution of a certain treatment and determine potentially a more optimal set of treatment parameters. This research contributes to the broader field of cancer research by laying the foundations for a digital tool for personalized pre-treatment planning. The insights gained could support interventional radiologists in optimizing treatment planning, improving tumor targeting, and minimizing radiation exposure to healthy liver tissue in future TARE procedures.",[547,548,549],"Hepatocellular Carcinoma (HCC)","Liver Cancer, Adult","Liver Cancer",[551,552,553,554,555,556],"Hepatocellular carcinoma","Transarterial radioembolization","Computational Fluid Dynamics","Personalized medicine","Pre-treatment planning","Monte Carlo Dosimetry calculations",{"date":529,"type":36},{"date":559,"type":36},"2025-09-23",{"date":117,"type":21},{"name":42,"class":43},{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":445,"minAge":18,"maxAge":272,"enrollmentInfo":570,"targetDuration":4,"studyType":55,"phases":572,"briefSummary":573,"conditions":574,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":584,"locationsCount":44},"100529596","phase-4-ppos-progestin-primed-ovarian-stimulation-and-corifollitropin-alfa-cfa-cross-over-study-100529596","NCT06175832","PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study","PPOS and CFA for Elective Freeze-all Ovarian Stimulation Cycles: a Prospective Cross-over Study","P-CCROSS","Prescreening: Clarification: Pre-screening might be performed to identify women with AFC \\> 5 and AMH \\> 1.1 ng\u002Fml (Bologna criteria, AFC and AMH values are valid for one year).\n\nInclusion criteria for:\n\n* Group 1: indication for oocyte cryopreservation\n* Group 2: indication for IVF\u002FICSI and PGT-A\n\nInclusion criteria for both groups:\n\n* First ovarian stimulation cycle\n* Aged ≥ 18 and \\\u003C 41 years old at the time of first OPU\n\nExclusion Criteria:\n\n* contra-indication for ovarian stimulation\n* expected poor ovarian response (Bologna Criteria)\n* PCOS patients\n* refusal to fill out questionnaires before, during and after treatment\n* simultaneous participation in another clinical study\n* untreated and uncontrolled thyroid dysfunction;\n* current use of oral contraceptives, anti-psychotics, anti-epileptics or chemotherapy;\n* pregnant or breastfeeding women. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.",{"count":571,"type":21},60,[350],"P-CCROSS is a randomized, prospective monocentric phase 4 study with a crossover study design. The aim of the study is to compare patient satisfaction (by means of questionnaires) and treatment compliance with IVF treatment with CFA (corifollitropin alfa) and PPOS (Progestin-Primed Ovarian Stimulation) versus conventional IVF treatment with a recombinant FSH\u002FGnRH antagonist. The study will also compare patients undergoing elective fertility preservation versus PGT-A (pre-implantation genetic testing for aneuploidy) patients.The study will have a crossover design so that patients will receive both forms of treatment. The investigators will also compare the endocrine profile and ovarian response of CFA\u002FPPOS versus rFSH\u002FGnRH ovarian stimulation cycles.",[575,576,577,578],"Ovarian Stimulation","Quality of Life","Preimplantation Genetic Testing","Fertility Preservation",{"date":580,"type":36},"2025-12-26",{"date":582,"type":36},"2025-01-27",{"date":535,"type":21},{"name":42,"class":43},{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":591,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":445,"minAge":593,"maxAge":594,"enrollmentInfo":595,"targetDuration":4,"studyType":55,"phases":597,"briefSummary":598,"conditions":599,"keywords":601,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":605,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":609,"locationsCount":44},"100505091","novasure-study-endometrial-ablation-in-women-with-heavy-menstrual-bleeding-100505091","NCT05856838","NovaSure Study: Endometrial Ablation in Women With Heavy Menstrual Bleeding","Radiofrequency Ablation in Women With Heavy Menstrual Bleeding, Procedure in an Outpatient Setting","RAMBOS","Inclusion Criteria:\n\n* ≥ 35 years - ≤ 50 years\n* Heavy menstrual bleeding (PBAC ≥ 150)\n* Unsuccessful drug treatment, contraindication to drug treatment or rejection of drug treatment by the patient\n* The absence of intra-uterine abnormalities on diagnostic hysteroscopy\n* Endometrial biopsy (pipelle) is normal\n* Finished childbearing\n\nExclusion Criteria:\n\n* Pregnancy\n* Endometritis\n* Adenomyosis\n* Contra-indication for local anaesthetics\n* Presence of severe systemic disease (≥ASA 3)\n* Previously performed endometrial ablation\n* Poor understanding of Dutch language\n* History of pelvic malignancy\n* Presence of an intra uterine device (IUD)\n* Cavity pathology (myoma, septum)\n* Cavity length \\\u003C 4 cm\n* Each uterine incision other than conventional caesarean incision","35 Years","50 Years",{"count":596,"type":21},30,[57],"Heavy menstrual bleeding (HMB) affects 30% of women worldwide. It negatively influences physical activity, work productivity, sexual life and overall quality of life.\n\nIn 2018, the FIGO (International Federation of Gynaecology and Obstetrics) revised its definition of AUB (FIGO-AUB system 1) and the classification of the underlying causes (FIGO-AUB system 2). It includes HMB, which is a subjective parameter and therefore patient determined. The FIGO-AUB system 2 describes the underlying causes of AUB through the acronym PALM-COEIN: Polyps, Adenomyosis, Leiomyomatosis, Malignancy, Coagulopathy, Endometrial, Iatrogenic and not otherwise specified.\n\nThe National Institute for Health and Care Excellence (NICE) guideline on HMB recommends the levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg as the treatment of first choice in women with no identified pathology, fibroids less than 3cm in diameter, which are not causing distortion of the uterine cavity, or adenomyosis. If a woman declines a LNG-IUS, non-hormonal (fibrinolytics or non-steroidal anti-inflammatory drugs (NSAIDs)) and other hormonal pharmacological treatments can be considered. If treatment is unsuccessful, the woman declines pharmacological treatment, or symptoms are severe, an endometrial ablation (EA) or hysterectomy can be an alternative option. The latter is a definitive solution, but it is an invasive option, with a risk of serious complications.\n\nAn EA is a procedure that destroys the endometrium. It aims to reduce the menstrual flow, sometimes causing amenorrhea. Initially, it was performed through hysteroscopy. Later on, second-generation devices became available. NovaSure is an example of a second-generation EA device, using a bipolar radiofrequency impedance-controlled system that evaporates endometrial tissue. The EA procedure is a minimally invasive alternative to hysterectomy. It is known to result in amenorrhea in 50% of women, with satisfaction rates between 80-96% and reported reintervention rates around 10%. Moreover, it is feasible to perform the procedure using only local anaesthesia.\n\nThe investigators aim to assess the patient acceptability and feasibility of NovaSure EA in an outpatient setting with a short observation (≤4 hours)\n\nThis observational prospective cohort study will be performed in the Ghent University Hospital (Ghent), Leuven Catholic University Hospital (Leuven) and Turnhout General Hospital (Turnhout).\n\nThe surgeon performing the procedure will be the same per institution. The duration of the study is estimated at 4 months.",[600],"Menstrual Bleeding, Heavy",[602,603,604],"Menorrhagia\u002Fsurgery","Endometrial Ablation Techniques","Endometrium\u002Fsurgery",{"date":580,"type":36},{"date":607,"type":36},"2023-11-24",{"date":203,"type":21},{"name":42,"class":43},{"id":611,"slug":612,"hasResults":12,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":616,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":445,"minAge":18,"maxAge":618,"enrollmentInfo":619,"targetDuration":4,"studyType":55,"phases":621,"briefSummary":622,"conditions":623,"keywords":625,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":44},"100613238","added-value-of-three-dimensional-transvaginal-ultrasound-3d-tvus-and-gel-infusion-sonography-3d-gis-compared-with-magnetic-resonance-imaging-mri-in-the-diagnosis-of-patients-with-suspicion-of-a-uterine-septum-100613238","NCT07263984","Added Value of Three-dimensional Transvaginal Ultrasound (3D TVUS) and Gel Infusion Sonography (3D GIS) Compared With Magnetic Resonance Imaging (MRI) in the Diagnosis of Patients With Suspicion of a Uterine Septum.","SEPTUM-D Project: Diagnosis in Patients With a Uterine Septum","SEPTUM-D","Inclusion Criteria:\n\n* Women aged between 18 and 45 years\n* With suspicion of a uterine septum on routine 2D TVUS\n* Who are willing to give informed consent\n\nExclusion Criteria:\n\n* Women aged below 18 years and over 45 years\n* Prior definitive diagnosis of a uterine septum or other congenital uterine anomaly\n* Prior surgery in relation to a uterine septum\n* Cervical (unilateral) aplasia\n* Vaginal aplasia\n* Untreated obstructive vaginal septum\n* Any co-morbidity that is found to interfere with the uterine measurements required in the study\n* Contraindications for MRI\n* Not willing or not possible to undergo transvaginal ultrasound\n* Pregnancy at the time of inclusion\n* Wish to conceive between inclusion and last diagnostic intervention\n* Visual or pathological evidence of cervical, uterine or ovarian malignancy\n* Patients with an intrauterine device (by mistake), who are not willing to remove this device before the start of the diagnostic interventions","45 Years",{"count":620,"type":21},145,[57],"The goal of this clinical trial is to investigate the added value of three-dimensional transvaginal ultrasound (3D TVUS) and gel infusion sonography (3D GIS) for diagnosing a partition in the uterus (uterine septum) in comparison to magnetic resonance imaging (MRI). The main question it aims to answer is:\n\nHow well do 3D TVUS and 3D GIS detect a uterine septum compared to MRI?\n\nParticipants will receive 3D TVUS\u002F 3D GIS and MRI, and will complete questionnaires.",[624],"Uterine Septum",[626,627,628,629,630],"Uterine septum","Diagnosis","Three-dimensional transvaginal ultrasound","Magnetic Resonance Imaging","Gel Infusion Sonography","2025-12-01",{"date":633,"type":36},"2025-12-04",{"date":635,"type":36},"2025-10-27",{"date":637,"type":21},"2028-10",{"name":42,"class":43},{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":645,"eligibilityCriteria":646,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":647,"targetDuration":4,"studyType":55,"phases":649,"briefSummary":650,"conditions":651,"keywords":653,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":658,"lastUpdatePostDateStruct":659,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":664,"locationsCount":44},"100530943","detection-of-endoscopic-resection-scars-and-delineation-of-recurrence-is-trainable-100530943","NCT06193356","Detection of Endoscopic Resection Scars and Delineation of Recurrence is Trainable","Detection of Endoscopic Resection Scars and Delineation of Recurrence Amongst Non-experts is Less Accurate Than Experts But Trainable in a Short Learning Intervention","SCAR","Inclusion Criteria:\n\n* Endoscopists of any experience level\n\nExclusion Criteria:\n\n* non consenting adults",{"count":648,"type":21},141,[57],"Colorectal cancer is prevented by colonoscopy and polypectomy. Failure to recognize the endoscopic resection scar after Endoscopic Mucosal Resection (EMR) risks unrecognized recurrent or residual adenoma (RRA), which may propagate into post-colonoscopy colorectal cancer. Expert series suggest scar recognition and interrogation is well performed with a high negative predictive value of endoscopic imaging vs histopathology. In this study the authors will investigate the performance of endoscopic imaging in detecting RRA at an endoscopic resection scar amongst general endoscopist and the impact of a learning intervention on recognition of RRA.\n\nAfter consent is given, the participant will open the online survey and fill this in.\n\nFirst the participant will be asked to create a pseudonym (name+year of birth) and fill in their demographical information (Grade, years in current role, colonoscopy experience, experience of colonic tissue resection, country of employment\n\nThe first 15 pictures will be shown prior to a learning intervention. For each picture the same questions will be asked:\n\n* Is this an endoscopic resection scar?\n* Based on this image does the scar demonstrate evidence of residual or recurrent adenoma (RRA)?\n* What is your level of confidence?\n* If the scar shows RRA, how would you treat it? (skip if you feel no RRA).\n* If the scar does not show RRA do you feel there is another diagnosis? After the first 15 pictures a video-based learning tool will be shown on detection of RRA.\n\nAfter the learning tool 15 different pictures will be shown, the same questions will be asked. All responses will be collected by the investigators. Statistical analysis will be performed using visual studio code (Microsoft, Redmond, USA) Images will be selected from the 'Australian Colonic LSL Endoscopic Resection Study' (ACE) database, which is an international multicentre registry of images and videos for retrospective analysis of colonic lesions. Images, videos, procedural information, and histopathological data are stored on a secure online web portal after written informed consent of every participating patient.",[652,131],"Colorectal Polyp",[654,655,656,657],"endoscopy","advanced imaging","post-colonoscopy colorectal cancer","Colorectal polypectomy","2025-11-19",{"date":660,"type":36},"2025-11-25",{"date":662,"type":36},"2024-11-11",{"date":388,"type":21},{"name":42,"class":43},""]